209 related articles for article (PubMed ID: 20516676)
1. A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily.
Tsuritani S; Nozaki T; Okumura A; Kimura H; Kazama T
Urol Int; 2010; 85(1):80-7. PubMed ID: 20516676
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
[TBL] [Abstract][Full Text] [Related]
3. [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
Akasaka T; Funaki H; Hirano S; Ohinata M; Fujishima M; Kudou T; Suzuki A; Iinuma M
Hinyokika Kiyo; 2003 Apr; 49(4):189-93. PubMed ID: 12784711
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
5. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
[TBL] [Abstract][Full Text] [Related]
6. α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Yamaguchi S; Osanai H; Numata A; Watanabe M; Kakizaki H
Int J Urol; 2013 May; 20(5):513-9. PubMed ID: 23078534
[TBL] [Abstract][Full Text] [Related]
7. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
Yokoyama T; Hara R; Fukumoto K; Fujii T; Jo Y; Miyaji Y; Nagai A; Sone A
Int J Urol; 2011 Mar; 18(3):225-30. PubMed ID: 21272091
[TBL] [Abstract][Full Text] [Related]
8. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].
Sakai H; Igawa T; Onita T; Furukawa M; Hakariya T; Hayashi M; Matsuya F; Shida Y; Nishimura N; Yogi Y; Tsurusaki T; Takehara K; Nomata K; Shiraishi K; Shono T; Aoki D; Kanetake H
Hinyokika Kiyo; 2011 Jan; 57(1):7-13. PubMed ID: 21304253
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of naftopidil on lower urinary tract symptoms after radical prostatectomy.
Ishizaka K; Machida T; Tanaka M; Kawamura N; Nakamura K; Kihara K
Int J Urol; 2009 Mar; 16(3):299-302. PubMed ID: 19207610
[TBL] [Abstract][Full Text] [Related]
11. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg.
Oh-oka H
Urol Int; 2009; 82(2):136-42. PubMed ID: 19321997
[TBL] [Abstract][Full Text] [Related]
13. [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
Sugino Y; Fukuzawa S; Takeuchi H; Taki Y; Hashimura T; Soeda T; Araki I
Hinyokika Kiyo; 2003 Aug; 49(8):445-9. PubMed ID: 14518379
[TBL] [Abstract][Full Text] [Related]
14. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
15. [Effect of KT-611 (Naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction].
Yamanaka N; Yamaguchi O; Kameoka H; Fukaya Y; Yokota T; Shiraiwa Y; Yokoyama J; Kumakawa K; Itou K; Kuma Y
Hinyokika Kiyo; 1991 Dec; 37(12):1759-72. PubMed ID: 1723843
[TBL] [Abstract][Full Text] [Related]
16. Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study.
Ukimura O; Kanazawa M; Fujihara A; Kamoi K; Okihara K; Miki T;
Int J Urol; 2008 Dec; 15(12):1049-54. PubMed ID: 19120513
[TBL] [Abstract][Full Text] [Related]
17. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
[TBL] [Abstract][Full Text] [Related]
18. Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications.
Fine SR; Ginsberg P
J Am Osteopath Assoc; 2008 Jul; 108(7):333-7. PubMed ID: 18648026
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
20. Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia.
Momose H; Hosokawa Y; Kishino T; Ono T; Oyama N
Drugs Today (Barc); 2007 Feb; 43 Suppl A():1-10. PubMed ID: 17401467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
